1,3-dihydro-1-phenyl-2H-indol-2-one | 1215121-49-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1,3-dihydro-1-phenyl-2H-indol-2-one
• 英文别名: 1-Phenylspiro[indole-3,4'-piperidine]-2-one
• CAS: 1215121-49-5
• 化学式: C₁₈H₁₈N₂O
• 分子量: 278.354
• InChiKey: UBUJOQAVSXAGHA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-tetrahydropyran-4-ylmethyl-piperidine-4-lithium-carboxylate 、 1,3-dihydro-1-phenyl-2H-indol-2-one 在 1,2-二氯乙烷 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 正丁醇 为溶剂， 反应 15.0h， 以41%的产率得到1'-[4-Fluoro-1-(oxan-4-ylmethyl)piperidine-4-carbonyl]-1-phenylspiro[indole-3,4'-piperidine]-2-one
  参考文献：
  名称：

  TRICYCLIC SPIROCYCLE DERIVATIVES AND METHODS OF USE

  摘要：

  本发明涉及新型三环螺环衍生物，包括该三环螺环衍生物的药物组合物，以及利用这些化合物治疗或预防过敏、过敏引起的气道反应、充血、心血管疾病、炎症性疾病、消化系统紊乱、神经系统紊乱、代谢紊乱、肥胖或与肥胖相关的疾病、糖尿病、糖尿病并发症、糖耐量受损或空腹血糖异常。

  公开号：

  US20110166124A1
• 作为产物：
  描述：

  1’-BOC-1,2-二氢-2-氧代-螺[3H-吲哚-3,4’-哌啶] 在 盐酸 、 copper(l) iodide 、 potassium carbonate 、 N,N'-二甲基乙二胺 作用下， 以 1,4-二氧六环 、 乙腈 为溶剂， 生成 1,3-dihydro-1-phenyl-2H-indol-2-one
  参考文献：
  名称：

  1,3,8-Triazaspiro[4.5]decane-2,4-diones as Efficacious Pan-Inhibitors of Hypoxia-Inducible Factor Prolyl Hydroxylase 1–3 (HIF PHD1–3) for the Treatment of Anemia

  摘要：

  The discovery of 1,3,8-triazaspiro[4.5]decane-2,4-diones (spirohydantoins) as a structural class of pan-inhibitors of the prolyl hydroxylase (PHD) family of enzymes for the treatment of anemia is described. The initial hit class, spirooxindoles, was identified through affinity selection mass spectrometry (AS-MS) and optimized for PHD2 inhibition and optimal PK/PD profile (short-acting PHDi inhibitors). 1,3,8-Triazaspiro[4.5]decane-2,4-diones (spirohydantoins) were optimized as an advanced lead class derived from the original spiroindole hit. A new set of general conditions for C-N coupling, developed using a high-throughput experimentation (HTE) technique, enabled a full SAR analysis of the spirohydantoins. This rapid and directed SAR exploration has resulted in the first reported examples of hydantoin derivatives with good PK in preclinical species. Potassium channel off-target activity (hERG) was successfully eliminated through the systematic introduction of acidic functionality to the molecular structure. Undesired upregulation of alanine aminotransferese (ALT) liver enzymes was mitigated and a robust on-/off-target margin was achieved. Spirohydantoins represent a class of highly efficacious, short-acting PHD1-3 inhibitors causing a robust erythropoietin (EPO) upregulation in vivo in multiple preclinical species. This profile deems spirohydantoins as attractive short-acting PHDi inhibitors with the potential for treatment of anemia.

  DOI：

  10.1021/jm201542d

文献信息

• [EN] TRICYCLIC SPIROCYCLE DERIVATIVES AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS SPIROCYCLIQUES TRICYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SCHERING CORP

  公开号：WO2010027567A2

  公开（公告）日：2010-03-11

  The present invention relates to novel Tricyclic Spirocycle Derivatives, pharmaceutical compositions comprising the Tricyclic Spirocycle Derivatives and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disoder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.
• TRICYCLIC SPIROCYCLE DERIVATIVES AND METHODS OF USE
  申请人：McCormick Kevin D.

  公开号：US20110166124A1

  公开（公告）日：2011-07-07

  The present invention relates to novel Tricyclic Spirocycle Derivatives, pharmaceutical compositions comprising the Tricyclic Spirocycle Derivatives and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or aired fasting glucose.

  本发明涉及新型三环螺环衍生物，包括该三环螺环衍生物的药物组合物，以及利用这些化合物治疗或预防过敏、过敏引起的气道反应、充血、心血管疾病、炎症性疾病、消化系统紊乱、神经系统紊乱、代谢紊乱、肥胖或与肥胖相关的疾病、糖尿病、糖尿病并发症、糖耐量受损或空腹血糖异常。
• 1,3,8-Triazaspiro[4.5]decane-2,4-diones as Efficacious Pan-Inhibitors of Hypoxia-Inducible Factor Prolyl Hydroxylase 1–3 (HIF PHD1–3) for the Treatment of Anemia
  作者：Petr Vachal、Shouwu Miao、Joan M. Pierce、Deodial Guiadeen、Vincent J. Colandrea、Matthew J. Wyvratt、Scott P. Salowe、Lisa M. Sonatore、James A. Milligan、Richard Hajdu、Anantha Gollapudi、Carol A. Keohane、Russell B. Lingham、Suzanne M. Mandala、Julie A. DeMartino、Xinchun Tong、Michael Wolff、Dietrich Steinhuebel、Gerard R. Kieczykowski、Fred J. Fleitz、Kevin Chapman、John Athanasopoulos、Gregory Adam、Can D. Akyuz、Dhirendra K. Jena、Jeffrey W. Lusen、Juncai Meng、Benjamin D. Stein、Lei Xia、Edward C. Sherer、Jeffrey J. Hale

  DOI：10.1021/jm201542d

  日期：2012.4.12

  The discovery of 1,3,8-triazaspiro[4.5]decane-2,4-diones (spirohydantoins) as a structural class of pan-inhibitors of the prolyl hydroxylase (PHD) family of enzymes for the treatment of anemia is described. The initial hit class, spirooxindoles, was identified through affinity selection mass spectrometry (AS-MS) and optimized for PHD2 inhibition and optimal PK/PD profile (short-acting PHDi inhibitors). 1,3,8-Triazaspiro[4.5]decane-2,4-diones (spirohydantoins) were optimized as an advanced lead class derived from the original spiroindole hit. A new set of general conditions for C-N coupling, developed using a high-throughput experimentation (HTE) technique, enabled a full SAR analysis of the spirohydantoins. This rapid and directed SAR exploration has resulted in the first reported examples of hydantoin derivatives with good PK in preclinical species. Potassium channel off-target activity (hERG) was successfully eliminated through the systematic introduction of acidic functionality to the molecular structure. Undesired upregulation of alanine aminotransferese (ALT) liver enzymes was mitigated and a robust on-/off-target margin was achieved. Spirohydantoins represent a class of highly efficacious, short-acting PHD1-3 inhibitors causing a robust erythropoietin (EPO) upregulation in vivo in multiple preclinical species. This profile deems spirohydantoins as attractive short-acting PHDi inhibitors with the potential for treatment of anemia.